Growing emphasis on disease-modifying therapies in Parkinson’s

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research..

With current treatments largely focused on motor symptoms, the pipeline across the seven major markets (7MM) highlights a growing emphasis on DMTs and non-motor symptom therapies, according to GlobalData.

Lorraine Palmer, pharma analyst at GlobalData, said: “There are a total of 93 products in Phase I to III development within the 7MM for the treatment of PD. Some 66% of these are prospective neuroprotective agents or DMTs. These investigational agents target the key mechanisms that have been implicated in the pathophysiology of PD, such as alpha-synuclein aggregation and neuroinflammation, with the goal of slowing disease progression.”